Skip to main content
SpringerLink
Log in

Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

A combination treatment with thymosin α1 (200 µg/kg) for 4 days, followed by a single injection of murine interferon α/β (3 × 104 international units/mouse), starting 2 days after cyclophosphamide treatment (200 mg/kg, single injection) demonstrated a dramatic and rapid disappearance of tumor burden in mice bearing Lewis lung carcinoma (3LL) tumor. The effectiveness of this new chemoimmunotherapy protocol was evident even on the long-term survival in a high percentage of animals, and was statistically significant when compared to treatment with the single agents in conjunction with chemotherapy or to chemotherapy itself. The same combination immunotherapy treatment strongly stimulated natural killer activity and cytotoxicity against autologus 3LL tumor cells in 3LL-tumor-bearing mice treated with cyclophosphamide, whereas treatments with each agent singly did not alter or only slightly modified the cytotoxic activity towards Yac-1 or 3LL target cells. Selective depletion with antibodies showed that killer cells stimulated by combination chemoimmunotherapy treatment bear phenotypic characteristics of asialo-GM1-positive cells. A histological study has shown a high number of infiltrating lymphoid cells in the tumors obtained from mice treated with combination chemoimmunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bilik R, Mor C, Hazaz B, Moroz C (1989) Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother 28: 143

    PubMed  Google Scholar 

  2. Bistoni F, Baccarini M, Blasi E, Pucetti P, Marconi P, Garaci E (1983) Correlation between in vivo and in vitro studies of the modulation of resistance to experimentalCandida albicans infection by cyclophosphamide in mice. Infect Immun 40: 46

    PubMed  Google Scholar 

  3. Cheever MA, Greenberg PD (1985) Adoptive cellular immunotherapy. In: Immunity to cancer. Academic Press, Orlando, p 453

    Google Scholar 

  4. Cohen MH, Chretien PB, Ihde DC, Fossieck BE, Makuch R, Bunn PA, Johnston AV, Shackney SE, Matthews MJ, Lipson SD, Kenady DE, Minna JD (1979) Thymosin fraction 5 and intensive combination chemotherapy prolonging the survival of patients with small-cell lung cancer. J Am Med Assoc 241: 1813

    Google Scholar 

  5. Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, Garaci E (1985) Modulation of natural killer activity by thymosin alpha 1 and interferon. Cancer Immunol Immunother 20: 189

    PubMed  Google Scholar 

  6. Favalli C, Mastino M, Jezzi T, Grelli S, Goldstein AL (1989) Synergistic effect of thymosin alpha 1 and alpha-beta interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol 5: 443

    Google Scholar 

  7. Forni G, Giovarelli M, Santoni A, Modesti A, Forni M (1986) Tumor inhibition by interleukin-2 at the tumor/host interface. Biochim Biophys Acta 865: 307

    PubMed  Google Scholar 

  8. Frasca D, Adorini L, Mancini C, Doria G (1986) Reconstitution of T-cell functions in aging mice by thymosin alpha 1. Immunopharmacology 11: 155

    PubMed  Google Scholar 

  9. Garaci E, Mastino A, Favalli C (1989) Enhanced immune response and antitumor immunity with combinations of biological response modifiers. Bull NY Acad Med 65: 111

    Google Scholar 

  10. Goldstein AL, Low TLK, Adoo M, McClure J, Thurman GB, Rossio G, Lay CY, Chang D, Wang SS, Harwey C, Ramel AH, Meienhofer J (1977) Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA 74: 725

    PubMed  Google Scholar 

  11. Goldstein AL, Schulof RS (1985) Thymosins in the treatment of cancer. In: Immunity to cancer. Academic Press, Orlando, p 469

    Google Scholar 

  12. Griffith KD, Read J, Carrasquillo JA, Carter CS, Yang JC, Fisher B, Aebersold P, Packard BS, Yu MY, Rosemberg SA (1989) In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81: 1709

    PubMed  Google Scholar 

  13. Hanna N (1986) In vivo activities of NK cells against primary and metastatic tumors in experimental animals. In: Immunobiology of natural killer cells. CRC Press, Boca Raton, Flq., p 1

    Google Scholar 

  14. Herberman RB (1985) Natural killer (NK) cells: characteristics and possible role in resistance against tumor growth. In: Immunity to cancer. Academic Press, Orlando, p 217

    Google Scholar 

  15. Herberman RB, Nunn ME, Lavrin DH (1975) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity. Int J Cancer 16: 216

    PubMed  Google Scholar 

  16. Hosokawa M, Sawamura Y, Morikage T, Okada F, Xu Z, Morikawa K, Itoh K, Kobayashi H (1988) Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother 26: 250

    PubMed  Google Scholar 

  17. Klein AS, Lang R, Eshel I, Sharabi Y, Shoham J (1987) Modulation of immune response and tumor development in tumor-bearing mice treated by the thymic factor thymostimulin. Cancer Res 47: 3351

    PubMed  Google Scholar 

  18. Lala PK, Santer V, Libenson H, Parhar RS (1985) Changes in the host natural killer cell population in mice during tumor development. I. Kinetics and in vivo significance. Cell Immunol 93: 250

    PubMed  Google Scholar 

  19. Mihich E (1985) Relationships between chemotherapy and immunotherapy: a brief overview. In: Rationale of biological response modifiers in cancer treatment. Excerpta Medica, Tokyo, p 105

    Google Scholar 

  20. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of established tumor depends on elimination of tumor induced suppressor cells. J Exp Med 155: 1063

    PubMed  Google Scholar 

  21. Papa MZ, Yang JC, Vetto JT, Shiloni E, Eisenthal A, Rosemberg SA (1988) Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res 48: 122

    PubMed  Google Scholar 

  22. Punturieri A, Santoni A, Ming WJ, Nobili N, Mantovani A, Bottazzi B (1989) In vitro migration of rat large granular lymphocytes. Cell Immunol 123: 257

    PubMed  Google Scholar 

  23. Serrate SA, Schulof RS, Leondaridis L, Goldstein AL, Sztein MB (1987) Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones. J Immunol 139: 2338

    PubMed  Google Scholar 

  24. Sztein MB, Serrate SA, Goldstein AL (1986) Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci USA 83: 6107

    PubMed  Google Scholar 

  25. Trinchieri G, Perussia B (1984) Biology of disease. Human natural killer cells: biologic and pathologic aspects. Lab Invest 50: 489

    PubMed  Google Scholar 

  26. Uchida A (1986) The cytolytic and regulatory role of natural killer cells in human neoplasia. Biochim Biophys Acta 865: 329

    PubMed  Google Scholar 

  27. Umeda Y, Sakamoto A, Nakamura J, Ishitsuka H, Yagui Y (1983) thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother 15: 78

    PubMed  Google Scholar 

  28. Wise JA, Mokyr MB, Dray S (1988) Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune response of spleen cells from mice bearing large MOPC-315 plasmacytomas. Cancer Immunol Immunother 27: 191

    PubMed  Google Scholar 

  29. Zatz MM, Oliver J, Samuels C, Skotnicki AB, Sztein MB, Goldstein AL (1985) Thymosin increases production of T cell growth factor by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 81: 2882

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Experimental Medicine and Biochemical Sciences, II University of Rome “Tor Vergata”, Via Orazio Raimondo, I-00173, Rome, Italy

    Enrico Garaci, Antonio Mastino, Francesca Pica & Cartesio Favalli

Authors
  1. Enrico Garaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Mastino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesca Pica
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cartesio Favalli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garaci, E., Mastino, A., Pica, F. et al. Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother 32, 154–160 (1990). https://doi.org/10.1007/BF01771450

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01771450

Keywords

Search

Navigation